Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in bladder cancer diagnostics.

Marta Sanchez-Carbayo1

  • 1Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. sanchezm@mskcc.org

Clinical Biochemistry
|July 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in laboratory medicine·2023
Same author

A new approach to prostate cancer screening.

Advances in laboratory medicine·2023
Same author

A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.

Cell death discovery·2020
Same author

Antiproliferative Activity of Olive Extract Rich in Polyphenols and Modified Pectin on Bladder Cancer Cells.

Journal of medicinal food·2020
Same author

Sirt1 protects from K-Ras-driven lung carcinogenesis.

EMBO reports·2018
Same author

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Urologic oncology·2018
Same journal

Analytical outlier rates for Roche fifth generation cardiac troponin T stat using biotin sensitive and insensitive reagent lots.

Clinical biochemistry·2026
Same journal

Evaluation of hemoglobin interference thresholds for chemical urinalysis panels.

Clinical biochemistry·2026
Same journal

Integrated genomic and biochemical diagnosis of a novel homozygous start-loss variant in AKR1D1 associated with neonatal cholestasis.

Clinical biochemistry·2026
Same journal

Agreement between POC glucose meters and blood gas analyzers varies across ICU patient populations.

Clinical biochemistry·2026
Same journal

From variability to value: Advancing vancomycin therapeutic drug monitoring toward decision-grade practice through commutability-informed external quality assessment and uncertainty-aware reporting.

Clinical biochemistry·2026
Same journal

Response to the letter to the editor: From variability to value: Advancing vancomycin therapeutic drug monitoring toward decision-grade practice through commutability-informed external quality assessment and uncertainty-aware reporting.

Clinical biochemistry·2026
See all related articles

High-throughput microarrays are revolutionizing bladder cancer research. These advanced tools help identify new diagnostic markers and therapeutic targets for transitional cell carcinoma of the bladder.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Transitional cell carcinoma of the bladder is a major global health concern.
  • Current diagnostic methods like cystoscopy and cytology have limitations in sensitivity and specificity.
  • Existing tumor markers lack the required performance for routine clinical use in bladder cancer detection.

Purpose of the Study:

  • To review the application of high-throughput microarrays in bladder cancer research.
  • To explore the implications of microarray analyses for diagnosing and managing bladder cancer.
  • To highlight the role of microarrays in identifying novel therapeutic targets and diagnostic tools.

Main Methods:

  • Systematic review of studies employing high-throughput microarrays in bladder cancer.

Related Experiment Videos

  • Analysis of data identifying molecular events and phenotypes associated with bladder tumors.
  • Evaluation of the impact of these findings on diagnostic and therapeutic strategies.

    • Main Results:

    • High-throughput microarrays are accelerating the discovery of molecular characteristics of bladder tumors.
    • These technologies are identifying novel therapeutic targets for bladder cancer.
    • Microarray data are contributing to the development of improved diagnostic tools for bladder cancer.

    Conclusions:

    • High-throughput microarrays offer significant potential for advancing bladder cancer diagnosis and management.
    • Continued research using these platforms is crucial for identifying new biomarkers and treatment strategies.
    • Microarray-driven insights are poised to improve clinical outcomes for patients with bladder cancer.